Where I came from:
Before joining GVSU in 2008, I was a postdoc in Sean
Morrison's lab at the U. of Michigan, and demonstrated that Rbpsuh, a
transcriptional co-factor for Notch signaling pathway, was necessary
for normal neural stem cell differentiation into glia in vivo. This
work allowed me to integrate my expertise in protein chemistry during
my PhD work (protein kinases and phosphoproteins) with cell signaling
and neural cell biology.
Why GVSU is special:
My lab’s research efforts have been shaped by the mission of
my institution and what we love: training the next generation of
scientists through excellent pedagogy in the classroom and pursuing
pressing questions at the bench. My lab is staffed by undergraduate
and masters level researchers (35% first generation college students;
85% of my students went on to attend graduate or professional school,
all are employed in the biomedical field). Training affects the scope
and speed of our progress, but the supportive environment here allows
us to ask high-risk questions with an extended timeline. Further, we
can leverage our discoveries to larger collaborative projects to solve
important questions in biology (students love being a part of this
What we do:
My lab works to determine how neural stem cells
differentiate into specific cell types during development.
Recently we applied in ovo electroporation to identify that the bHLH
gene Nato3 can promote dopamine (DA) neuron related genes in vivo, and
that phosphorylation-mimicking modifications of this gene (dubbed
“PM-Nato3”) can broaden the efficacy of Nato3 to drive these genes
broadly in the CNS. The dopamine neuron relate genes that are
upregulated include those that are important in DA neurogenesis and
protection of DA neurons from conditions that mimic Parkinson’s disease.
Thus PM-Nato3 has the potential to make DA neurons for PD
patients and/or protect PD patient’s DA neurons from further degeneration.
This work has led to a patent filing, support from the NIH, NSF, as
well as the Michigan Economic Development Corporation to identify
therapeutic and commercialization potential.
We currently have three main interests:
- The mechanism of Nato3 action on promoting expression of DA neuron
related genes (Campbell Foundation supported work within our lab).
- Using PM-Nato3 to differentiate human embryonic stem cells into DA
neurons (MEDC supported collaboration with University of Michigan’s
human stem cell and genome editing core facility).
- Using PM-Nato3 to protect dopamine neurons from parkinsonian
conditions in cell culture and in animal models (NIH supported
collaboration with Patrik Brundin at Van Andel Research Institute
and Jeffery Kordower at Rush University).
Currently seeking a postdoc position for this work! Please see
the following links:
My expertise in cell biology and protein chemistry are best
illustrated in the following publications and patent filings:
Taylor MK, Yeager K, Morrison SJ., Physiological
Notch signaling promotes gliogenesis in the developing peripheral and
central nervous systems. Development 2007 Jul; 134(13):2435-47
Taylor MK, Straight J, Peterson D, Huisingh N, Doyle
D., Nato3 mutant polypeptides and uses thereof. International Patent
Application No. PCT/US16/62876 Unpublished (filing date Nov. 20, 2015).
MK, Uhler MD., The amino-terminal cyclic nucleotide
binding site of the type II cGMP-dependent protein kinase is essential
for full cyclic nucleotide dependent activation. Journal of
Biological Chemistry 2000 Sep 8;275(36):28053-62
DeLano-Taylor Contact Information